Management of late-presenting patients with HIV infection

被引:15
作者
Rockstroh, Juergen K. [1 ]
Gatell, Jose [2 ]
Landman, Roland [3 ]
Antinori, Andrea [4 ]
机构
[1] Univ Bonn, Dept Med 1, D-5300 Bonn, Germany
[2] Univ Barcelona, Clin Inst Infect Dis & Immunol, Hosp Clin, Barcelona, Spain
[3] Bichat Claude Bernard Hosp, AP HP, Serv Malad Infect & Trop, Paris, France
[4] INMI Osped L Spallanzani, Direttore Dipartimento Clin, IRCCS, Rome, Italy
关键词
ACTIVE ANTIRETROVIRAL THERAPY; ONCE-DAILY DARUNAVIR/RITONAVIR; HIV-1-INFECTED PATIENTS; COMBINATION THERAPY; CLINICAL MANAGEMENT; DRUG-RESISTANCE; TREATMENT-NAIVE; TUBERCULOSIS; DISEASE; ADULTS;
D O I
10.3851/IMP1527
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Managing patients who present late with HIV infection is challenging. All late-presenting patients should have an individual treatment plan that encompasses both anti-retroviral therapy and, where necessary, treatment for opportunistic diseases. Timely initiation of treatment in late presenters is crucial but the optimal time to start therapy depends on many individual factors, including the presence of opportunistic infection and potential drug-drug interactions. Primary drug resistance is an important contributor to poor clinical outcomes in HIV; resistance profiling before treatment initiation is therefore recommended. The choice of initial HIV treatment should reflect patient characteristics, the results of resistance testing and the complexity of concomitant disease.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 47 条
[1]   Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Na⟨ve to Antiretroviral Therapy [J].
Antinori, A. ;
Ammassari, A. ;
Torti, C. ;
Marconi, P. ;
Andreoni, M. ;
Angarano, G. ;
Bonora, S. ;
Castagna, A. ;
Cauda, R. ;
Clerici, M. ;
Monforte, A. d'Arminio ;
De Luca, A. ;
Di Perri, G. ;
Galli, M. ;
Girardi, E. ;
Gori, A. ;
Lazzarin, A. ;
Lo Caputo, S. ;
Mazzotta, F. ;
Montella, F. ;
Mussini, C. ;
Perno, C. F. ;
Puoti, M. ;
Rizzardini, G. ;
Rusconi, S. ;
Vullo, V. ;
Carosi, G. .
INFECTION, 2009, 37 (03) :270-282
[2]   Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation [J].
Antinori, Andrea ;
Johnson, Margaret ;
Moreno, Santiago ;
Yazdanpanah, Yazdan ;
Rockstroh, Juergen K. .
ANTIVIRAL THERAPY, 2010, 15 :31-35
[3]  
Baalwa J, 2008, AFR HEALTH SCI, V8, P190
[4]   An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults [J].
Bartlett, John A. ;
Fath, Michael J. ;
DeMasi, Ralph ;
Hermes, Ashwaq ;
Quinn, Joseph ;
Mondou, Elsa ;
Rousseau, Franck .
AIDS, 2006, 20 (16) :2051-2064
[5]   Antiretroviral therapy of late presenters with advanced HIV disease [J].
Battegay, Manuel ;
Fehr, Jan ;
Flueckiger, Ursula ;
Elzi, Luigia .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (01) :41-44
[6]   Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies [J].
Boffito, M. ;
Pillay, D. ;
Wilkins, E. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (09) :1098-1106
[7]  
*CDCP, 2008, MMWR-MORBID MORTAL W, V58, P1
[8]   European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults [J].
Clumeck, N. ;
Pozniak, A. ;
Raffi, F. .
HIV MEDICINE, 2008, 9 (02) :65-71
[9]   Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy [J].
Curkendall, S. M. ;
Richardson, J. T. ;
Emons, M. F. ;
Fisher, A. E. ;
Everhard, F. .
HIV MEDICINE, 2007, 8 (08) :483-490
[10]  
*DEP HLTH HUM SERV, 2009, PAN ANT GUID AD AD G